| Name | cyclin dependent kinase (protein family or complex) |
|---|---|
| Synonyms | cyclin dependent kinase; cyclin dependent kinases |
| Name | kinetin |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19138471 | Zhou Y, Guo YJ, Liu X, Mei YW: Cell cycle inhibitor enhances the resolution of HSV-1-induced proinflammatory response in murine microglial cells. Neurol Res. 2009 Nov;31(9):910-6. Epub 2009 Jan 9. Recently, cyclin-dependent kinases (CDKs) have been found to act as cellular targets for antiviral drugs. |
1(0,0,0,1) | Details |
| 15705874 | Maude SL, Enders GH: Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res. 2005 Feb 1;65(3):780-6. Cyclin-dependent kinases (Cdk) promote cell proliferation, are often deregulated in human cancers, and are targets of ongoing cancer chemotherapy trials. |
1(0,0,0,1) | Details |
| 11380680 | Waring P, Mullbacher A: Cell death mediated by alloreactive cytotoxic T cells via the granule exocytosis or the Fas pathway is independent of p34cdc2 kinase: Fas dependent killing of cells arrested in the cell cycle. Immunol Cell Biol. 2001 Jun;79(3):264-73. This toxin causes increased intracellular rises that then result in irreversible inhibition of cyclin dependent kinases, including p34cdc2 kinase. |
1(0,0,0,1) | Details |
| 9344580 | Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L, Ramaekers FC: The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res. 1997 Oct 10;236(1):4-15. |
1(0,0,0,1) | Details |
| 9552391 | Kim SH, Schulze-Gahmen U, Brandsen J, de Azevedo Junior WF: Structural basis for chemical inhibition of CDK2. . Prog Cell Cycle Res. 1996;2:137-45. The central role of cyclin-dependent kinases (CDKs) in cell cycle regulation makes them a promising target for discovering small inhibitory molecules that can modify the degree of cell proliferation. |
1(0,0,0,1) | Details |
| 10851267 | Atienza C Jr, Elliott MJ, Dong YB, Yang HL, Stilwell A, Liu TJ, McMasters KM: Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors. Int J Mol Med. 2000 Jul;6(1):55-63. |
6(0,0,0,6) | Details |
| 17003520 | Schmid G, Strosznajder JB, Wesierska-Gadek J: Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors. Mol Neurobiol. 2006 Aug;34(1):27-50. Cyclin-dependent kinases (Cdks) play a key role in orchestrating the coordination of cell cycle progression in proliferating cells. |
1(0,0,0,1) | Details |
| 9621021 | Schang LM, Phillips J, Schaffer PA: Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J Virol. 1998 Jul;72(7):5626-37. |
1(0,0,0,1) | Details |
| 10506210 | Liu CW, Wang RH, Dohadwala M, Schonthal AH, Villa-Moruzzi E, Berndt N: Inhibitory phosphorylation of PP1alpha catalytic subunit during the G (1)/S transition. J Biol Chem. 1999 Oct 8;274(41):29470-5. We have shown earlier that, in cells expressing the retinoblastoma protein (pRB), a protein phosphatase (PP) 1alpha mutant (T320A) resistant to inhibitory phosphorylation by cyclin-dependent kinases (Cdks) causes G (1) arrest. |
1(0,0,0,1) | Details |
| 9030781 | Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243(1-2):527-36. |
5(0,0,0,5) | Details |
| 16000586 | Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P: In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res. 2005 Jul 1;11(13):4875-87. |
5(0,0,0,5) | Details |
| 14653808 | Penuelas S, Alemany C, Noe V, Ciudad CJ: The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors. Eur J Biochem. 2003 Dec;270(24):4809-22. |
4(0,0,0,4) | Details |
| 9742142 | Ratner N, Bloom GS, Brady ST: A role for cyclin-dependent kinase (s) in the modulation of fast anterograde axonal transport: effects defined by olomoucine and the APC tumor suppressor protein. J Neurosci. 1998 Oct 1;18(19):7717-26. |
3(0,0,0,3) | Details |
| 10725241 | Corellou F, Bisgrove SR, Kropf DL, Meijer L, Kloareg B, Bouget FY: A S/M DNA replication checkpoint prevents nuclear and cytoplasmic events of cell division including centrosomal axis alignment and inhibits activation of cyclin-dependent kinase-like proteins in fucoid zygotes. Development. 2000 Apr;127(8):1651-60. |
3(0,0,0,3) | Details |
| 9006970 | Park DS, Morris EJ, Greene LA, Geller HM: G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis. J Neurosci. 1997 Feb 15;17(4):1256-70. |
2(0,0,0,2) | Details |
| 9930732 | Sankrithi N, Eskin A: Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia. J Neurochem. 1999 Feb;72(2):605-13. |
2(0,0,0,2) | Details |
| 17008397 | Konstantopoulos N, Marcuccio S, Kyi S, Stoichevska V, Castelli LA, Ward CW, Macaulay SL: A kinase inhibitor, calcium/calmodulin-dependent protein kinase II inhibitor 59, reveals a role for calcium/calmodulin-dependent protein kinase II in insulin-stimulated transport. Endocrinology. 2007 Jan;148(1):374-85. Epub 2006 Sep 28. Olomoucine is known as a cyclin-dependent kinase inhibitor. |
1(0,0,0,1) | Details |
| 11684672 | Corellou F, Brownlee C, Kloareg B, Bouget FY: Cell cycle-dependent control of polarised development by a cyclin-dependent kinase-like protein in the Fucus zygote. Development. 2001 Nov;128(21):4383-92. |
2(0,0,0,2) | Details |
| 9268294 | Trzepacz C, Lowy AM, Kordich JJ, Groden J: Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34. J Biol Chem. 1997 Aug 29;272(35):21681-4. |
2(0,0,0,2) | Details |
| 9030780 | De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH: Inhibition of cyclin-dependent kinases by analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem. 1997 Jan 15;243(1-2):518-26. |
2(0,0,0,2) | Details |
| 10660590 | Romanowski P, Marr J, Madine MA, Rowles A, Blow JJ, Gautier J, Laskey RA: Interaction of Xenopus Cdc2 x cyclin A1 with the origin recognition complex. J Biol Chem. 2000 Feb 11;275(6):4239-43. The kinase activity is sensitive to several inhibitors of cyclin-dependent kinases including (6- olomoucine, and p21 (Cip1). |
2(0,0,0,2) | Details |
| 16096806 | Manhani KK, Arcuri HA, da Silveira NJ, Uchoa HB, de Azevedo WF Jr, Canduri F: Molecular models of protein kinase 6 from Plasmodium falciparum. J Mol Model. 2005 Dec;12(1):42-8. Epub 2005 Nov 4. Cyclin-dependent kinases (CDKs) have been identified as potential targets for development of drugs, mainly against cancer. |
1(0,0,0,1) | Details |
| 15130771 | Monaco EA 3rd, Beaman-Hall CM, Mathur A, Vallano ML: Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. Biochem Pharmacol. 2004 May 15;67(10):1947-64. Cyclin-dependent kinases (CDKs) mediate proliferation and neuronal development, while aberrant CDK activity is associated with cancer and neurodegeneration. |
1(0,0,0,1) | Details |
| 10378797 | Papazisis KT, Geromichalos GD, Kouretas D, Dimitriadis KA, Kortsaris AH: CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside. Cancer Lett. 1999 Apr 26;138(1-2):221-6. Signal transduction for apoptosis or programmed cell death, after DNA damage in mammalian cells, is believed to involve activation of cyclin-dependent kinases (CDKs), especially CDK-1 (cdc2) and CDK-2. |
1(0,0,0,1) | Details |
| 15591654 | Wesierska-Gadek J, Gueorguieva M, Wojciechowski J, Horky M: Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine. Pol J Pharmacol. 2004 Sep-Oct;56(5):635-41. |
2(0,0,0,2) | Details |
| 16386795 | Travnicek Z, Krystof V, Sipl M: (II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity. J Inorg Biochem. 2006 Feb;100(2):214-25. Epub 2006 Jan 4. |
2(0,0,0,2) | Details |
| 9436644 | Hajduch M, Kolar Z, Novotny R, Hanus J, Mihal V, Hlobilkova A, Noskova V, Strnad M: Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine. Anticancer Drugs. 1997 Nov;8(10):1007-13. |
2(0,0,0,2) | Details |
| 15951378 | Buraei Z, Anghelescu M, Elmslie KS: Slowed N-type calcium channel (CaV2.2) deactivation by the cyclin-dependent kinase inhibitor roscovitine. Biophys J. 2005 Sep;89(3):1681-91. Epub 2005 Jun 10. |
2(0,0,0,2) | Details |
| 7549905 | Abraham RT, Acquarone M, Andersen A, Asensi A, Belle R, Berger F, Bergounioux C, Brunn G, Buquet-Fagot C, Fagot D, et al.: Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. . Biol Cell. 1995;83(2-3):105-20. |
1(0,0,0,1) | Details |
| 9514874 | Nuckolls FJ, Khan AS, Butler R, Katula KS: Differential response of the human cyclin B1 promoter to inhibitors of the cell cycle in NIH3T3 cells. Biochem Biophys Res Commun. 1998 Mar 6;244(1):280-4. In this study, NIH3T3 cells stably transfected with a cyclin B1-luciferase reporter vector were utilized to investigate if cyclin B1 promoter activity is linked to either DNA replication or the activities of various cyclin-cyclin dependent kinases (cdks). |
1(0,0,0,1) | Details |
| 9871543 | Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L: Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorg Med Chem Lett. 1998 Apr 7;8(7):793-8. |
2(0,0,0,2) | Details |
| 9046330 | Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Strnad M: Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem. 1997 Feb 14;40(4):408-12. |
2(0,0,0,2) | Details |
| 19250292 | Jhou RS, Sun KH, Sun GH, Wang HH, Chang CI, Huang HC, Lu SY, Tang SJ: Inhibition of cyclin-dependent kinases by olomoucine and roscovitine reduces lipopolysaccharide-induced inflammatory responses via down-regulation of nuclear factor kappaB. Cell Prolif. 2009 Apr;42(2):141-9. Epub 2009 Feb 24. |
2(0,0,0,2) | Details |
| 9828096 | Alessi F, Quarta S, Savio M, Riva F, Rossi L, Stivala LA, Scovassi AI, Meijer L, Prosperi E: The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp Cell Res. 1998 Nov 25;245(1):8-18. |
2(0,0,0,2) | Details |
| 11986377 | Furukawa T, Ogura T, Zheng YJ, Tsuchiya H, Nakaya H, Katayama Y, Inagaki N: Phosphorylation and functional regulation of ClC-2 channels expressed in Xenopus oocytes by M cyclin-dependent protein kinase. J Physiol. 2002 May 1;540(Pt 3):883-93. We show here that the volume-sensitive Cl (-) channel, ClC-2 is regulated by the M-phase-specific cyclin-dependent kinase, p34 (cdc2)/cyclin B. |
1(0,0,0,1) | Details |
| 18761330 | Wesierska-Gadek J, Hajek SB, Sarg B, Wandl S, Walzi E, Lindner H: Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells. Biochem Pharmacol. 2008 Dec 1;76(11):1503-14. Epub 2008 Aug 12. Escape from the proper control of the cell cycle by up-regulation of cyclins or aberrant activation of cyclin-dependent kinases (CDKs) as well as by inactivation of cellular inhibitors of CDKs (CKI) leads to malignant transformation. |
1(0,0,0,1) | Details |
| 9437005 | Park DS, Morris EJ, Stefanis L, Troy CM, Shelanski ML, Geller HM, Greene LA: Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci. 1998 Feb 1;18(3):830-40. As with NGF deprivation and camptothecin treatment, the cyclin-dependent kinase inhibitors flavopiridol and olomoucine protected neurons from apoptosis induced by AraC and UV treatment. |
1(0,0,0,1) | Details |
| 18841444 | An R, Hagiya Y, Tamura A, Li S, Saito H, Tokushima D, Ishikawa T: Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res. 2009 Feb;26(2):449-58. Epub 2008 Oct 9. |
2(0,0,0,2) | Details |
| 11271495 | Kovarova H, Hajduch M, Korinkova G, Halada P, Krupickova S, Gouldsworthy A, Zhelev N, Strnad M: Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Electrophoresis. 2000 Nov;21(17):3757-64. |
2(0,0,0,2) | Details |
| 9288122 | Iseki H, Ko TC, Xue XY, Seapan A, Hellmich MR, Townsend CM Jr: Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery. 1997 Aug;122(2):187-94; discussion 194-5. |
2(0,0,0,2) | Details |
| 11434907 | Harmse L, van Zyl R, Gray N, Schultz P, Leclerc S, Meijer L, Doerig C, Havlik I: Structure-activity relationships and inhibitory effects of various derivatives on the in vitro growth of Plasmodium falciparum. Biochem Pharmacol. 2001 Aug 1;62(3):341-8. Cyclin-dependent kinases (CDKs) are essential for the regulation of the eukaryotic cell cycle, and several enzymes of this family have been identified in P. falciparum. |
1(0,0,0,1) | Details |
| 10597222 | Baldassarre G, Barone MV, Belletti B, Sandomenico C, Bruni P, Spiezia S, Boccia A, Vento MT, Romano A, Pepe S, Fusco A, Viglietto G: Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation. Oncogene. 1999 Nov 4;18(46):6241-51. |
1(0,0,0,1) | Details |
| 9841966 | Iseki H, Ko TC, Xue XY, Seapan A, Townsend CM Jr: A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. J Gastrointest Surg. 1998 Jan-Feb;2(1):36-43. |
1(0,0,0,1) | Details |
| 9553063 | Grant KM, Hassan P, Anderson JS, Mottram JC: The crk3 gene of Leishmania mexicana encodes a stage-regulated cdc2-related histone H1 kinase that associates with p12. J Biol Chem. 1998 Apr 24;273(17):10153-9. Data presented here suggests that crk3 is a good candidate to be the leishmanial cdc2 homologue but that the parasite protein has some characteristics which distinguish it from mammalian cdc2. crk3 is predicted to encode a 35.6-kDa protein with 54% sequence identity with the human cyclin-dependent kinase cdc2 and 78% identity with the Trypanosoma brucei CRK3. |
1(0,0,0,1) | Details |
| 12882273 | Blagoeva E, Malbeck J, Gaudinova A, Vanek T, Vankova R: Cyclin-dependent kinase inhibitor, roscovitine, in combination with exogenous cytokinin, N6-benzyladenine, causes increase of cis-cytokinins in immobilized tobacco cells. Biotechnol Lett. 2003 Mar;25(6):469-72. |
2(0,0,0,2) | Details |
| 10542199 | Choi KS, Eom YW, Kang Y, Ha MJ, Rhee H, Yoon JW, Kim SJ: Cdc2 and Cdk2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells. J Biol Chem. 1999 Nov 5;274(45):31775-83. During TGF-beta1-induced apoptosis, the transient increase in cyclin-dependent kinase (Cdk) activities coincides with a dramatic increase in the hyperphosphorylated forms of RB. |
1(0,0,0,1) | Details |
| 11254958 | Gomez EB, Santori MI, Laria S, Engel JC, Swindle J, Eisen H, Szankasi P, Tellez-Inon MT: Characterization of the Trypanosoma cruzi Cdc2p-related protein kinase 1 and identification of three novel associating cyclins. Mol Biochem Parasitol. 2001 Mar;113(1):97-108. Lastly, using the yeast two-hybrid system we identified three novel cyclin-like proteins able to associate with TzCRK1, and demonstrate that two of these cyclins also bind the T. cruzi CRK3 protein, indicating that these two CRKs are cyclin-dependent kinases. |
1(0,0,0,1) | Details |
| 17975794 | Wesierska-Gadek J, Gueorguieva M, Kramer MP, Ranftler C, Sarg B, Lindner H: A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein. J Cell Biochem. 2007 Dec 15;102(6):1405-19. Inhibition of cyclin-dependent kinases (CDKs) is a novel strategy in the therapy of human malignancies. |
1(0,0,0,1) | Details |
| 9300578 | Buquet-Fagot C, Lallemand F, Montagne MN, Mester J: Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines. Anticancer Drugs. 1997 Jul;8(6):623-31. |
1(0,0,0,1) | Details |
| 9552377 | Meijer L: Chemical inhibitors of cyclin-dependent kinases. . Prog Cell Cycle Res. 1995;1:351-63. |
2(0,0,0,2) | Details |
| 11438580 | Katchanov J, Harms C, Gertz K, Hauck L, Waeber C, Hirt L, Priller J, von Harsdorf R, Bruck W, Hortnagl H, Dirnagl U, Bhide PG, Endres M: Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. J Neurosci. 2001 Jul 15;21(14):5045-53. |
2(0,0,0,2) | Details |
| 16530228 | Appert-Collin A, Hugel B, Levy R, Niederhoffer N, Coupin G, Lombard Y, Andre P, Poindron P, Gies JP: Cyclin dependent kinase inhibitors prevent apoptosis of postmitotic mouse motoneurons. Life Sci. 2006 Jun 27;79(5):484-90. Epub 2006 Mar 10. |
2(0,0,0,2) | Details |
| 10495356 | Gray N, Detivaud L, Doerig C, Meijer L: ATP-site directed inhibitors of cyclin-dependent kinases. . Curr Med Chem. 1999 Sep;6(9):859-75. |
2(0,0,0,2) | Details |
| 19368812 | Fei XF, Qin ZH, Xiang B, Li LY, Han F, Fukunaga K, Liang ZQ: Olomoucine inhibits cathepsin L nuclear translocation, activates autophagy and attenuates toxicity of Brain Res. 2009 Apr 6;1264:85-97. Epub 2009 Feb 6. Olomoucine, a cyclin dependent kinase (CDK) inhibitor, reduced contralateral rotations and the loss of TH-positive neurons in substantia nigra induced by lesion with 6-OHDA. |
1(0,0,0,1) | Details |
| 11052627 | Lu K, Shih C, Teicher BA: Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents. Cancer Chemother Pharmacol. 2000;46(4):293-304. |
1(0,0,0,1) | Details |
| 12147712 | Mad'arova J, Lukesova M, Hlobilkova A, Strnad M, Vojtesek B, Lenobel R, Hajduch M, Murray PG, Perera S, Kolar Z: Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines. Mol Pathol. 2002 Aug;55(4):227-34. One potential tool is the use of cyclin dependent kinase (CDK) inhibitors, which are based on the trisubstituted derivatives of |
1(0,0,0,1) | Details |
| 11251098 | Corellou F, Brownlee C, Detivaud L, Kloareg B, Bouget FY: Cell cycle in the fucus zygote parallels a somatic cell cycle but displays a unique translational regulation of cyclin-dependent kinases. Plant Cell. 2001 Mar;13(3):585-98. |
2(0,0,0,2) | Details |
| 11896531 | Vermeulen K, Strnad M, Krystof V, Havlicek L, Van der Aa A, Lenjou M, Nijs G, Rodrigus I, Stockman B, van Onckelen H, Van Bockstaele DR, Berneman ZN: Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases. Leukemia. 2002 Mar;16(3):299-305. |
2(0,0,0,2) | Details |
| 8626506 | Park DS, Farinelli SE, Greene LA: Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J Biol Chem. 1996 Apr 5;271(14):8161-9. |
2(0,0,0,2) | Details |
| 15331409 | Zhang M, Li J, Chakrabarty P, Bu B, Vincent I: Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am J Pathol. 2004 Sep;165(3):843-53. |
2(0,0,0,2) | Details |
| 10567774 | Fan S, Duba DE, O'Connor PM: Cellular effects of olomoucine in human lymphoma cells differing in p53 function. Chemotherapy. 1999 Nov-Dec;45(6):437-45. Olomoucine, a derivative, inhibits multiple cyclin-dependent kinases that play important roles in regulating the G1/S and G2/M transitions of the cell cycle. |
1(0,0,0,1) | Details |
| 16243312 | Ribas J, Gomez-Arbones X, Boix J: Caspase 8/10 are not mediating apoptosis in neuroblastoma cells treated with CDK inhibitory drugs. Eur J Pharmacol. 2005 Nov 7;524(1-3):49-52. Epub 2005 Oct 21. Olomoucine and Roscovitine are pharmacological inhibitors of cyclin-dependent kinases (CDK) displaying a promising profile as anticancer agents. |
1(0,0,0,1) | Details |
| 15557790 | Blasco F, Penuelas S, Cascallo M, Hernandez JL, Alemany C, Masa M, Calbo J, Soler M, Nicolas M, Perez-Torras S, Gomez A, Tarrason G, Noe V, Mazo A, Ciudad CJ, Piulats J: Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy. Oncology. 2004;67(3-4):277-90. We analyzed the differential gene expression in the pancreatic cancer cell line NP-18 upon induction of apoptosis caused by cyclin-dependent kinase inhibition triggered by either overexpression of the tumor suppressor gene p16 (INK4A) using an adenoviral construction or incubation with the chemical inhibitors, roscovitine or olomoucine. |
1(0,0,0,1) | Details |
| 9353591 | Krucher NA, Meijer L, Roberts MH: The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker. Cell Mol Neurobiol. 1997 Oct;17(5):495-507. |
2(0,0,0,2) | Details |
| 12899660 | Cervenkova K, Belejova M, Chmela Z, Rypka M, Riegrova D, Michnova K, Michalikova K, Surova I, Brejcha A, Hanus J, Cerny B, Fuksova K, Havlicek L, Vesely J: In vitro glycosidation potential towards olomoucine-type cyclin-dependent kinase inhibitors in rodent and primate microsomes. Physiol Res. 2003;52(4):467-74. |
2(0,0,0,2) | Details |
| 9523556 | Maas JW Jr, Horstmann S, Borasio GD, Anneser JM, Shooter EM, Kahle PJ: Apoptosis of central and peripheral neurons can be prevented with cyclin-dependent kinase/mitogen-activated protein kinase inhibitors. J Neurochem. 1998 Apr;70(4):1401-10. |
2(0,0,0,2) | Details |
| 9500988 | Yakisich JS, Siden A, Idoyaga Vargas V, Eneroth P, Cruz M: Early inhibition of DNA synthesis in the developing rat cerebral cortex by the analogues olomoucine and roscovitine. Biochem Biophys Res Commun. 1998 Feb 24;243(3):674-7. The effects of the cyclin-dependent kinase (CDK) inhibitors olomoucine and roscovitine on DNA synthesis were studied using short time incubation (30-90 minutes). |
1(0,0,0,1) | Details |
| 18207409 | Wang W, Redecker C, Yu ZY, Xie MJ, Tian DS, Zhang L, Bu BT, Witte OW: Rat focal cerebral ischemia induced astrocyte proliferation and delayed neuronal death are attenuated by cyclin-dependent kinase inhibition. J Clin Neurosci. 2008 Mar;15(3):278-85. Epub 2008 Jan 22. |
2(0,0,0,2) | Details |
| 17094472 | Boutis A, Papazisis K, Pistevou-Gompaki K, Lambropoulos A, Sofroniadis I, Papageorgiou A, Destouni E, Kortsaris A: Cyclin-dependent kinase (CDK) inhibitor olomoucine enhances gamma-irradiation-induced apoptosis and cell cycle arrest in Raji cells. Anticancer Res. 2006 Sep-Oct;26(5A):3493-8. |
2(0,0,0,2) | Details |
| 15640940 | Knillova J, Bouchal J, Hlobilkova A, Strnad M, Kolar Z: Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines. Neoplasma. 2004;51(5):358-67. |
2(0,0,0,2) | Details |
| 10840869 | Flament S, Bodart JF, Bertout M, Browaeys E, Rousseau A, Vilain JP: Differential effects of 6- olomoucine and roscovitine on Xenopus oocytes and eggs. Zygote. 2000 Feb;8(1):3-14. The effects of the new cyclin-dependent kinase inhibitors, roscovitine and olomoucine, on oocytes and eggs of Xenopus laevis were investigated and compared with those of 6-dimethylamino (6- |
1(0,0,0,1) | Details |
| 16820010 | Cho S, Meriney SD: The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Eur J Neurosci. 2006 Jun;23(12):3200-8. We used (R)-roscovitine, a cyclin-dependent kinase inhibitor that also appears to act directly on channels, as a tool to modulate presynaptic influx and study effects on transmitter release. |
1(0,0,0,1) | Details |
| 10871858 | Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F: Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene. 2000 Jun 22;19(27):3059-68. In this study, we report that derivative cyclin-dependent kinase (Cdk) inhibitors, roscovitine and olomoucine, dramatically enhance this FTI-induced apoptosis of human cancer cell lines. |
1(0,0,0,1) | Details |
| 15240808 | Li C, Sasaki Y, Takei K, Yamamoto H, Shouji M, Sugiyama Y, Kawakami T, Nakamura F, Yagi T, Ohshima T, Goshima Y: Correlation between semaphorin3A-induced facilitation of axonal transport and local activation of a translation initiation factor eukaryotic translation initiation factor 4E. J Neurosci. 2004 Jul 7;24(27):6161-70. Lavendustin A, a kinase inhibitor, and olomoucine, a cyclin-dependent kinase inhibitor, suppressed Sema3A-induced facilitation of anterograde and retrograde axonal transport in dorsal root ganglion (DRG) neuron with and without the cell body. |
1(0,0,0,1) | Details |
| 14743398 | Sharma MR, Tuszynski GP, Sharma MC: Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem. 2004 Feb 1;91(2):398-409. In dividing cells, cell cycle-associated protein kinases, which are referred as cyclin-dependent kinases (cdks), regulate proliferation, differentiation, senescence, and apoptosis. |
1(0,0,0,1) | Details |
| 11773377 | Muller B, Patschinsky T, Krausslich HG: The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles. J Virol. 2002 Feb;76(3):1015-24. Inhibition experiments suggested that a cyclin-dependent kinase or a related kinase, most likely ERK2, was involved in p6 phosphorylation by virion-associated enzymes. |
1(0,0,0,1) | Details |
| 7479711 | Schulze-Gahmen U, Brandsen J, Jones HD, Morgan DO, Meijer L, Vesely J, Kim SH: Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins. 1995 Aug;22(4):378-91. Cyclin-dependent kinases (CDKs) are conserved regulators of the eukaryotic cell cycle with different isoforms controlling specific phases of the cell cycle. |
1(0,0,0,1) | Details |
| 9315091 | Resnick RJ, Taylor SJ, Lin Q, Shalloway D: Phosphorylation of the Src substrate Sam68 by Cdc2 during mitosis. Oncogene. 1997 Sep;15(11):1247-53. Cdc2 was identified as the kinase responsible for the mitotic phosphorylation by (1) immunodepletion of the mitotic Sam68 kinase from cell lysates with anti-Cdc2 antibodies, (2) inhibition of Sam68 phosphorylation in vitro and in vivo by the cyclin-dependent kinase inhibitor olomoucine and (3) phosphorylation of Sam68 by purified Cdc2. |
1(0,0,0,1) | Details |
| 10465404 | Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Giocanti N, Sadri R, Favaudon V: Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorg Med Chem. 1999 Jul;7(7):1281-93. |
1(0,0,0,1) | Details |
| 19723061 | Wandl S, Wesierska-Gadek J: Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?. Ann N Y Acad Sci. 2009 Aug;1171:242-9. Olomoucine (OLO), a substituted analogue, is a much weaker inhibitor of cyclin-dependent kinases than other closely related ATP derivatives. |
1(0,0,0,1) | Details |
| 15827328 | Jiang H, Zhang L, Kuo J, Kuo K, Gautam SC, Groc L, Rodriguez AI, Koubi D, Hunter TJ, Corcoran GB, Seidman MD, Levine RA: -induced apoptotic death in human U251 glioma cells. Mol Cancer Ther. 2005 Apr;4(4):554-61. The cyclin-dependent kinase inhibitor, olomoucine, prevents cell cycle progression and -induced apoptosis. |
1(0,0,0,1) | Details |
| 9737000 | Trehin C, Planchais S, Glab N, Perennes C, Tregear J, Bergounioux C: Cell cycle regulation by plant growth regulators: involvement of auxin and cytokinin in the re-entry of Petunia protoplasts into the cell cycle. Planta. 1998 Oct;206(2):215-24. Roscovitine, a cyclin-dependent kinase (CDK) inhibitor, was found to block the cell cycle prior to entry into the S and M phases in the cultured P. hybrida protoplasts. |
1(0,0,0,1) | Details |